![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Seiter Karen
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.4, Iss.2, 2005-03, pp. : 219-234
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Toxicity of the topoisomerase I inhibitors
By Seiter Karen
Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dual Topoisomerase I / II Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry, Vol. 3, Iss. 3, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry, Vol. 19, Iss. 23, 2012-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
DNA topoisomerase II inhibitors: new approaches to antitumour therapy
Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. :